Mark Honzel, MD
Addiction Medicine · Beverly Hills, CANPI 1083761670
Payments from drug & device makers
Across 1,275 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Gilead$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Lundbeck LLC$2K
- Viiv Healthcare Company$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $14K from 51 others
What the payments were for
- Speaking & faculty fees$1270%
- Food & beverage$27,11199%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIXADI$111
How this compares
$27,263 in reported general payments places this provider in the 95th percentile of 190 addiction medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SerostimSomatropin | 182 | $3,627,263 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 38 | $734,305 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 169 | $663,040 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 11 | $555,072 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $257,530 |
| Egrifta SvTesamorelin Acetate | 32 | $229,311 |
| TivicayDolutegravir Sodium | 82 | $201,277 |
| JulucaDolutegravir/Rilpivirine | 37 | $131,802 |
| DescovyEmtricitabine/Tenofov Alafenam | 50 | $124,029 |
| RelistorMethylnaltrexone Bromide | 49 | $115,394 |
| PrezcobixDarunavir/Cobicistat | 22 | $52,461 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $49,568 |
| JardianceEmpagliflozin | 75 | $48,463 |
| XifaxanRifaximin | 14 | $42,014 |
| Oxymorphone Hcl ErOxymorphone Hcl | 12 | $40,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Serostim | $514 | $3,627,263182 claims |
| GileadBiktarvy, Descovy | $2,636 | $787,069219 claims |
| Viiv Healthcare CompanyTivicay, Juluca | $1,863 | $333,079119 claims |
| Grifols USA, LLCGamunex-C | $57 | $257,53026 claims |
| Theratechnologies Inc.Egrifta Sv | $446 | $229,31132 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor, Xifaxan | $1,395 | $157,40963 claims |
| Lilly USA, LLCMounjaro, Trulicity | $154 | $64,96162 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $1,411 | $59,02535 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $33 | $54,89788 claims |
| AbbVieVraylar, Linzess | $3,520 | $38,83034 claims |
| MerckJanuvia | $305 | $23,40932 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,078 | $15,34211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 190 addiction medicine providers in California.
Other addiction medicine in Beverly Hills
- Jonathan ReitmanBeverly Hills$11K
- Tipu KhanVentura$262K
- Anthony AlbaneseMather$135K
- Matthew TorringtonCulver City$77K
- Kenneth StarrArroyo Grande$64K
- Drew PinskySouth Pasadena$60K
- Bryan HylerVista$17K
- Faried BanimahdSanta Ana$16K
- Abraham MalkinLos Angeles$12K
- Caleb LuskSan Pedro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.